Clinical application of a 3D ultrasound-guided prostate biopsy system

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 3, 2011, Pages 334-342

  Natarajan, Shyam ^a   Marks, Leonard S ^b   Margolis, Daniel J A ^b   Huang, Jiaoti ^b   Macairan, Maria Luz ^b   Lieu, Patricia ^b   Fenster, Aaron ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Artemis; Biopsy; Cancer; Diffusion weighted imaging; MRI; Prostate

Indexed keywords

ADULT; AGED; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL EVALUATION; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; ECHOGRAPHY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REAL TIME ECHOGRAPHY; REVIEW; THREE DIMENSIONAL IMAGING; TRANSRECTAL ULTRASONOGRAPHY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; HUMANS; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; PROSTATIC NEOPLASMS;

EID: 79955714408     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.02.014     Document Type: Review

References (62)

1. Walsh P.C. 2008 Whitmore Lecture: Radical prostatectomy-where we were and where we are going. Urol Oncol 2009, 27:246-250.
2. Stamey T.A., Caldwell M., McNeal J.E., et al. The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years?. J Urol 2004, 172:1297-1301.
3. Epstein J.I., Walsh P.C., Carmichael M., et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994, 271:368-374.
4. Sutcliffe P., Hummel S., Simpson E., et al. Use of classical and novel biomarkers as prognostic risk factors for localized prostate cancer: A systematic review. Health Technol Assess 2009, 13:1-219.
5. Cooperberg M.R., Broering J.M., Kantoff P.W., et al. Contemporary trends in low risk prostate cancer: Risk assessment and treatment. J Urol 2007, 178:S14-S19.
6. Carter H.B., Sauvageot J., Walsh P.C., et al. Prospective evaluation of men with stage T1c adenocarcinoma of the prostate. J Urol 1997, 157:2206-2209.
7. Klotz L., Zhang L., Lam A., et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010, 28:126-131.
8. Hambrock T., Somford D.M., Hoeks C., et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 2010, 183:520-528.
9. Hricak H., Choyke P.L., Eberhardt S.C., et al. Imaging prostate cancer: A multidisciplinary perspective. Radiology 2007, 243:28-53.
10. Kim C.K., Park B.K., Kim B. Diffusion-weighted MRI at 3 T for the evaluation of prostate cancer. Am J Roentgenol 2010, 194:1461-1469.
11. Lawrentschuk N., Fleshner N. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU international 2009, 103:730-733.
12. Dooms G.C., Hricak H. Magnetic resonance imaging of the pelvis: Prostate and urinary bladder. Urol Radiol 1986, 8:156-165.
13. Narayan P., Vigneron D.B., Jajodia P., et al. Transrectal probe for 1H MRI and 31P MR spectroscopy of the prostate gland. Magn Reson Med 1989, 11:209-220.
14. Outwater E.K., Petersen R.O., Siegelman E.S., et al. Prostate carcinoma: Assessment of diagnostic criteria for capsular penetration on endorectal coil MR images. Radiology 1994, 193:333-339.
15. Brown G., Macvicar D., Ayton V., et al. The role of intravenous contrast enhancement in magnetic resonance imaging of prostatic carcinoma. Clin Radiol 1995, 50:601-606.
16. Jager G., Ruijter E., Van de Kaa C., et al. Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: Correlation with histopathologic results. Radiology 1997, 203:645-652.
17. Engelbrecht M.R., Huisman H.J., Laheij R.J.F., et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003, 229:248.
18. Quint L., Van Erp J., Bland P., et al. Prostate cancer: Correlation of MR images with tissue optical density at pathologic examination. Radiology 1991, 179:837-842.
19. Kozlowski P., Chang S.D., Jones E.C., et al. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis-correlation with biopsy and histopathology. J Magn Reson 2006, 24:108-113.
20. Ocak I., Bernardo M., Metzger G., et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: A study of pharmacokinetic parameters. Am J Roentgenol 2007, 189:W192-W201.
21. Tanimoto A., Nakashima J., Kohno H., et al. Prostate cancer screening: The clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson 2007, 25:146-152.
22. Oto A., Kayhan A., Jiang Y., et al. Prostate cancer: Differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 2010, 257:715-723.
23. Turkbey B., Xu S., Kruecker J., et al. Documenting the location of prostate biopsies with image fusion. BJU Intl 2010, 107:53-57.
24. Kitajima K., Kaji Y., Fukabori Y., et al. Prostate cancer detection with 3 T MRI: Comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson 2010, 31:625-631.
25. Langer D.L., van der Kwast T.H., Evans A.J., et al. Prostate tissue composition and MR measurements: Investigating the relationships between ADC, T2, Ktrans, ve, and corresponding histologic features. Radiology 2010, 255:485-494.
26. Park B.K., Lee H.M., Kim C.K., et al. Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen level using diffusion-weighted imaging at 3 Tesla before re-biopsy. Invest Radiol 2008, 43:789-793.
27. Xu S., Kruecker J., Turkbey B., et al. Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comp Aid Surg 2008, 13:255-264.
28. Turkbey B., Pinto P.A., Mani H., et al. Prostate Cancer: Value of multiparametric MR imaging at 3 T for detection-histopathologic correlation. Radiology 2010, 255:89-99.
29. Rastinehad A.R., Baccala A.A., Chung P.H., et al. D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. J Urol 2011, 185:815-820.
30. Fütterer J.J., Heijmink S.W., Scheenen T.W.J., et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006, 241:449-458.
31. Chen M., Dang H.D., Wang J.Y., et al. Prostate cancer detection: Comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the 3 techniques combined. Acta Radiologica 2008, 49:602-610.
32. Riches S.F., Payne G.S., Morgan V.A., et al. MRI in the detection of prostate cancer: Combined apparent diffusion coefficient, metabolite ratio, and vascular parameters. Am J Roentgenol 2009, 193:1583-1591.
33. Weinreb J.C., Blume J.D., Coakley F.V., et al. Prostate cancer: Sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy-results of ACRIN prospective multi-institutional clinicopathologic study. Radiology 2009, 251:122-133.
34. Heijmink S.W., Fütterer J.J., Hambrock T., et al. Prostate cancer: Body-array vs. endorectal coil MR imaging at 3 T-comparison of image quality, localization, and staging performance. Radiology 2007, 244:184-195.
35. Park B.K., Kim B., Kim C.K., et al. Comparison of phased-array 3.0-T and endorectal 1.5-T magnetic resonance imaging in the evaluation of local staging accuracy for prostate cancer. J Comput Assist Tomogr 2007, 31:534-538.
36. Alonzi R., Padhani A.R., Allen C. Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiol 2007, 63:335-350.
37. van Dorsten F.A., van der Graaf M., Engelbrecht M.R.W., et al. Combined quantitative dynamic contrast-enhanced MR imaging and 1H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 2004, 20:279-287.
38. Padhani A.R., Gapinski C.J., Macvicar D.A., et al. Dynamic contrast enhanced MRI of prostate cancer: Correlation with morphology and tumor stage, histological grade, and PSA. Clinical Radiol 2000, 55:99-109.
39. Fütterer J.J., Engelbrecht M.R., Huisman H.J., et al. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: Experienced vs. less experienced readers. Radiology 2005, 237:541-549.
40. Girouin N., Mege-Lechevallier F., Tonina Senes A., et al. Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: Is it reasonable?. Eur Radiol 2007, 17:1498-1509.
41. Sinha S., Sinha U. In vivo diffusion tensor imaging of the human prostate. Magn Reson Med 2004, 52:530-537.
42. Pickles M.D., Gibbs P., Sreenivas M., et al. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0 T. J Magn Reson 2006, 23:130-134.
43. Gibbs P., Liney G.P., Pickles M.D., et al. Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Investig Radiol 2009, 44:572-576.
44. Haider M.A., van der Kwast T.H., Tanguay J., et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. Am J Roentgenol 2007, 189:323-328.
45. van As N., Charles-Edwards E., Jackson A., et al. Correlation of diffusion-weighted MRI with whole mount radical prostatectomy specimens. Br J Radiol 2008, 81:456-462.
46. Yoshimitsu K., Kiyoshima K., Irie H., et al. Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: Correlation with stepwise histopathology. J Magn Reson 2008, 27:132-139.
47. Mazaheri Y., Hricak H., Fine S.W., et al. Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: Correlation with pathologic tumor volume. Radiology 2009, 252:449-457.
48. Woodfield C.A., Tung G.A., Grand D.J., et al. Diffusion-weighted MRI of peripheral zone prostate cancer: Comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. Am J Roentgenol 2010, 194:W316-W322.
49. de Souza N., Reinsberg S., Scurr E., et al. Magnetic resonance imaging in prostate cancer: The value of apparent diffusion coefficients for identifying malignant nodules. Br J Radiol 2007, 80:90-95.
50. de Souza N., Riches S., Vanas N., et al. Diffusion-weighted magnetic resonance imaging: A potential non-invasive marker of tumor aggressiveness in localized prostate cancer. Clin Radiol 2008, 63:774-782.
51. van As N.J., de Souza N.M., Riches S.F., et al. A study of diffusion-weighted magnetic resonance imaging in men with untreated localized prostate cancer on active surveillance. Eur Urol 2009, 56:981-988.
52. Lee S.H., Park K.K., Choi K.H., et al. Is endorectal coil necessary for the staging of clinically localized prostate cancer?. Comparison of non-endorectal vs. endorectal MR imaging. World J Urol 2010, 28:667-672.
53. Bax J., Cool D., Gardi L., et al. Mechanically assisted 3D ultrasound guided prostate biopsy system. Med Phys 2008, 35:5397-5410.
54. Marks L., Ward A., Gardi L., et al. Tracking of prostate biopsy sites using a 3D ultrasound device (Artemis). J Urol 2010, 183:e832.
55. Rankin R., Fenster A., Downey D., et al. Three-dimensional sonographic reconstruction: Techniques and diagnostic applications. Am J Roentgenol 1993, 161:695-702.
56. Ahmed H.U., Kirkham A., Arya M., et al. Is it time to consider a role for MRI before prostate biopsy?. Nat Rev Clin Oncol 2009, 6:197-206.
57. Raz O., Haider M., Trachtenberg J., et al. MRI for men undergoing active surveillance or with rising PSA and negative biopsies. Nat Rev Urol 2010, 7:543-551.
58. Rosset A., Spadola L., Ratib O. OsiriX: An open-source software for navigating in multidimensional DICOM images. J Digit Imag 2004, 17:205-216.
59. Ladak H., Mao F., Wang Y., et al. Prostate boundary segmentation from 2D ultrasound images. Med Phys 2000, 27:1777-1788.
60. Wang Y., Cardinal N., Downey D., et al. Semi-automatic 3D segmentation of the prostate using 2D ultrasound images. Med Phys 2003, 30:88-97.
61. Narayanan R., Kurhanewicz J., Shinohara K., et al. MRI-ultrasound registration for targeted prostate biopsy. IEEE Intl Symp Biomed Imaging 2009, 991-994.
62. Karnik V., Fenster A., Bax J., et al. Assessment of image registration accuracy in 3-dimensional transrectal ultrasound guided prostate biopsy. Med Phys 2010, 37:802-813.